35 related articles for article (PubMed ID: 9661637)
1. Effects of p53-expressing adenovirus on the chemosensitivity and differentiation of anaplastic thyroid cancer cells.
Blagosklonny MV; Giannakakou P; Wojtowicz M; Romanova LY; Ain KB; Bates SE; Fojo T
J Clin Endocrinol Metab; 1998 Jul; 83(7):2516-22. PubMed ID: 9661637
[TBL] [Abstract][Full Text] [Related]
2. Genetic alterations in thyroid cancer mediating both resistance to BRAF inhibition and anaplastic transformation.
Lee M; Morris LG
Oncotarget; 2024 Jan; 15():36-48. PubMed ID: 38275291
[TBL] [Abstract][Full Text] [Related]
3. Roles of reactive oxygen species, mitochondrial membrane potential, and p53 in evodiamine-induced apoptosis and G2/M arrest of human anaplastic thyroid carcinoma cells.
Chien CC; Wu MS; Chou SW; Jargalsaikhan G; Chen YC
Chin Med; 2021 Dec; 16(1):134. PubMed ID: 34886886
[TBL] [Abstract][Full Text] [Related]
4. Survival Benefit of Intervention Treatment in Advanced Anaplastic Thyroid Cancer.
Kasemsiri P; Chaisakgreenon P; Vatanasapt P; Laohasiriwong S; Teeramatwanich W; Thongrong C; Ratanaanekchai T; Suetrong S
Int J Surg Oncol; 2021; 2021():5545127. PubMed ID: 34123423
[TBL] [Abstract][Full Text] [Related]
5. PI3K blockage synergizes with PLK1 inhibition preventing endoreduplication and enhancing apoptosis in anaplastic thyroid cancer.
De Martino D; Yilmaz E; Orlacchio A; Ranieri M; Zhao K; Di Cristofano A
Cancer Lett; 2018 Dec; 439():56-65. PubMed ID: 30243708
[TBL] [Abstract][Full Text] [Related]
6. TERT promoter mutations are a major indicator of recurrence and death due to papillary thyroid carcinomas.
Bullock M; Ren Y; O'Neill C; Gill A; Aniss A; Sywak M; Sidhu S; Delbridge L; Learoyd D; de Vathaire F; Robinson BG; Clifton-Bligh RJ
Clin Endocrinol (Oxf); 2016 Aug; 85(2):283-90. PubMed ID: 26667986
[TBL] [Abstract][Full Text] [Related]
7. New small molecules, ISA27 and SM13, inhibit tumour growth inducing mitochondrial effects of p53.
Sorriento D; Del Giudice C; Bertamino A; Ciccarelli M; Gomez-Monterrey I; Campiglia P; Novellino E; Illario M; Trimarco B; De Luca N; Iaccarino G
Br J Cancer; 2015 Jan; 112(1):77-85. PubMed ID: 25422906
[TBL] [Abstract][Full Text] [Related]
8. Progress in oncolytic virotherapy for the treatment of thyroid malignant neoplasm.
Guan M; Romano G; Coroniti R; Henderson EE
J Exp Clin Cancer Res; 2014 Nov; 33():91. PubMed ID: 25366264
[TBL] [Abstract][Full Text] [Related]
9. The PTTG1-binding factor (PBF/PTTG1IP) regulates p53 activity in thyroid cells.
Read ML; Seed RI; Fong JC; Modasia B; Ryan GA; Watkins RJ; Gagliano T; Smith VE; Stratford AL; Kwan PK; Sharma N; Dixon OM; Watkinson JC; Boelaert K; Franklyn JA; Turnell AS; McCabe CJ
Endocrinology; 2014 Apr; 155(4):1222-34. PubMed ID: 24506068
[TBL] [Abstract][Full Text] [Related]
10. The role of chemotherapy and latest emerging target therapies in anaplastic thyroid cancer.
Denaro N; Nigro CL; Russi EG; Merlano MC
Onco Targets Ther; 2013 Sep; 9():1231-41. PubMed ID: 24092989
[TBL] [Abstract][Full Text] [Related]
11. Enlarging neck masses in the elderly - Histological and surgical considerations.
O'Sullivan MD; McAnena KS; Egan C; Waters PS; McCann PJ; Kerin MJ
Int J Surg Case Rep; 2013; 4(4):378-81. PubMed ID: 23500736
[TBL] [Abstract][Full Text] [Related]
12. Anaplastic thyroid cancer: a review of epidemiology, pathogenesis, and treatment.
Nagaiah G; Hossain A; Mooney CJ; Parmentier J; Remick SC
J Oncol; 2011; 2011():542358. PubMed ID: 21772843
[TBL] [Abstract][Full Text] [Related]
13. Angio-adaptation in unloaded skeletal muscle: new insights into an early and muscle type-specific dynamic process.
Roudier E; Gineste C; Wazna A; Dehghan K; Desplanches D; Birot O
J Physiol; 2010 Nov; 588(Pt 22):4579-91. PubMed ID: 20876198
[TBL] [Abstract][Full Text] [Related]
14. Gene medicine for cancer treatment: commercially available medicine and accumulated clinical data in China.
Ma G; Shimada H; Hiroshima K; Tada Y; Suzuki N; Tagawa M
Drug Des Devel Ther; 2009 Feb; 2():115-22. PubMed ID: 19920899
[TBL] [Abstract][Full Text] [Related]
15. Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies.
Smallridge RC; Marlow LA; Copland JA
Endocr Relat Cancer; 2009 Mar; 16(1):17-44. PubMed ID: 18987168
[TBL] [Abstract][Full Text] [Related]
16. Conditionally replicating adenoviruses for cancer treatment.
Jounaidi Y; Doloff JC; Waxman DJ
Curr Cancer Drug Targets; 2007 May; 7(3):285-301. PubMed ID: 17504125
[TBL] [Abstract][Full Text] [Related]
17. Surgical options in undifferentiated thyroid carcinoma.
Lang BH; Lo CY
World J Surg; 2007 May; 31(5):969-77. PubMed ID: 17483987
[TBL] [Abstract][Full Text] [Related]
18. New trends in the treatment of undifferentiated carcinomas of the thyroid.
Miccoli P; Materazzi G; Antonelli A; Panicucci E; Frustaci G; Berti P
Langenbecks Arch Surg; 2007 Jul; 392(4):397-404. PubMed ID: 17131154
[TBL] [Abstract][Full Text] [Related]
19. Cell cycle regulator E2F1 modulates angiogenesis via p53-dependent transcriptional control of VEGF.
Qin G; Kishore R; Dolan CM; Silver M; Wecker A; Luedemann CN; Thorne T; Hanley A; Curry C; Heyd L; Dinesh D; Kearney M; Martelli F; Murayama T; Goukassian DA; Zhu Y; Losordo DW
Proc Natl Acad Sci U S A; 2006 Jul; 103(29):11015-20. PubMed ID: 16835303
[TBL] [Abstract][Full Text] [Related]
20. Potential activity of paclitaxel, vinorelbine and gemcitabine in anaplastic thyroid carcinoma.
Voigt W; Kegel T; Weiss M; Mueller T; Simon H; Schmoll HJ
J Cancer Res Clin Oncol; 2005 Sep; 131(9):585-90. PubMed ID: 16021466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
